In a novel public engagement event designed to showcase the potential benefits of personalised cancer medicine, Almac Diagnostics, a leading personalised medicine company, opened its doors to cancer patients in Northern Ireland enabling them to see “Science in Action” and how partnerships between industry and academia have the potential to benefit patients suffering from the disease.
Speaking at this special event, Jo-Anne Dobson, local Member of the Northern Ireland Assembly (Parliament) for Upper Bann and recently elected Chair of the All Party Group on Cancer said “This is a really important event for cancer patients as it allows them to see first-hand how a local company with an international reputation is working to develop new tests that can make a difference in this deadly disease”.
As part of the event, cancer patients had the opportunity to step inside the laboratories at Almac Diagnostics and meet some of the scientists who are involved in this innovative work.
Prof Paul Harkin, President and Managing Director of Almac Diagnostics commented “Almac are delighted to be involved with the S:CORT precision medicine initiative. We are fully committed to the advancement of personalised medicine and are currently developing a number of predictive and prognostic diagnostic tests with utility for colon cancer patients.”
The S:CORT Consortium highlights how collaboration between all stakeholders - patients, researchers, healthcare professionals, industry, research charities and policy organisations can be so effective. “Working in silos does not help the patient” said Prof Lawler. “Yes, we need to compete – not against each other but against our common enemy – Cancer”